Biotech | April 03, 2022
USFDA approves Yescarta as first CAR T-cell therapy for Lymphoma
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
A new course at the Azrieli Faculty of Medicine will focus on tissue regeneration and 3D printing for therapeutic needs
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
Subscribe To Our Newsletter & Stay Updated
